No Detail Found!

An Insight to Hyperhomocysteinaemia in CKD Patients of a Tertiary Care Hospital, Karachi

Author(s)
Nadia Yaqub Department of Chemical Pathology, Indus Hospital and Health Network,Karachi,Pakistan
Adnan Mustafa Zubairi Department of Chemical Pathology, Indus Hospital and Health Network,Karachi,Pakistan
Fatima Kanani Department of Chemical Pathology, Indus Hospital and Health Network,Karachi,Pakistan
Maliha Zubairy Department of Chemical Pathology, Indus Hospital and Health Network,Karachi,Pakistan
Ayesha Iftikhar Department of Chemical Pathology, Indus Hospital and Health Network,Karachi,Pakistan
Abstract
Objective: To evaluate the frequency and association of hyperhomocysteinaemia (HHcy) in di erent stages of chronic kidney disease (CKD) patients. Study Design: Cross-sectional, descriptive study. Place and Duration of the Study: Department of Chemical Pathology, Indus Hospital and Health Network Karachi, Pakistan, from July to December 2022. Methodology: Blood samples of 100 known CKD patients were collected for this study. The estimated glomerular ltration rate (eGFR) was calculated from the CKD-EPI calculator for CKD staging. Plasma homocysteine (Hcy) and serum creatinine concentrations were analysed on Abbott Alinity I and C analyzers, respectively. The SPSS was used for data compilation and analysis. Descriptive statistics were calculated. The association of HHcy with CKD and other variables was assessed using the Chi-square test as appropriate. A p-value of d0.05 was considered as signi cant. Results: Out of total 100, 52% males and 48% females known CKD patients were included in the study. The mean age of the patients was 50.62 ± 16.29 years. The median eGFR,serum creatinine, and Homocysteine were 18 ml/min/1.73m2, 3.48mg/dl, and 20.07 ¼mol/l, respectively.The percentage of CKD patients in each stage was 7% in stage 3a, 18% in stage 3b, 30% in stage 4, and 45% in stage 5. HHcy was observed in 79% of the CKD patients and among them 7.6% patients were in stage 3a, 19.0% in stage 3b, 31.6% in stage 4, and 41.8 % in stage 5. Conclusion: Patients with CKD were found to have HHcy indicating a very high level of prevalence in CKD patients, especially in the late stages. Hence, Hcy can be considered as a predictor of advancing disease. Timely interventions are required to prevent future adverse outcomes and improve the quality of life in CKD patients. However, a signi cant association was not seen between Hcy concentration and eGFR stages in the current study.
Publication Details
Page(s) 180-184
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 35, Issue: 2, Year: 2025

Request the full text from PASTIC

Keywords
Mortality, Cardiovascular disease, End-stage renal disease, Hyperhomocysteinaemia, Estimated glomerular ltration rate, CKD-EPI calculator
References
Lameire NH,Levin A,Kellum JA,Cheung M,Jadoul M,Winkelmayer WC .2021 .Harmonizing acute and chronic kidney disease de nition and classi cation: Report of a kidney disease: Improving global outcomes (KDIGO) consensus conference. Kidney Int, 06(3) : 516-26.
Bikbov B,Purcell CA,Levey SA,Smith M,Abdoli A,Abebe M. GBD .2020 .A systematic analysis for the global burden of disease study 2017. Lancet, 6736(20) : 30045-3.
Hasan M,Sutradhar I,Gupta RD,Sarker M. .2018 .Prevalence of chronic kidney disease in South Asia: A systematic review. BMC Nephrol, 10(1) : 291.
Ahmed J,Azhar S,Haq NU,Hussain S,Stajer A,Urban E .2022 .Awareness of chronic kidney disease, medication, and laboratory investigation among nephrology and urology patients of Quetta, Pakistan. Int J Environ Res Public Health, 19(9) : .
Ye Z,Zhang Q,Li Y,Wang C,Zhang J,Ma X .2016 .High prevalence of Hyperhomocysteinaemia and its association with target organ damage in Chinese patients with chronic kidney disease. Nutrients, 10(10) : 645.
Rehman T,Shabbir MA,Raheem MIU,Manzoor MF,Ahmad N,Liu ZW .1818 .Cysteine and homocysteine as biomarker of various diseases. Food Sci Nutr, 10(9) : 4696-707.
Angelini A,Cappuccilli ML,Magnoni G,Chiocchini ALC,Aiello V,Napoletano A .2021 .The link between homocysteine, folic acid and vitamin B12 in chronic kidney disease. G Ital Nefrol, 38(4) : 2021-4.
Friedman AN,Bostom AG,Selhub J,Levey AS,Rosenberg IH .2001 .The kidney and homocysteine metabolism. J Am Soc Nephrol, 2181(10) : 2181-9.
Kim J,Kim H,Roh H,Kwon Y. .2018 .Causes of hyperhomocysteinaemia and its pathological signi cance. Arch Pharm Res, 10(4) : 372-83.
Koklesova L,Mazurakova A,Samec M,Biringer K,Samuel SM,Busselberg D .2021 .Homocysteine metabolism as the target for predictive medical approach, disease prevention, prognosis, and treatments tailored to the person. EPMA J, 10(4) : 477-505.
Moon H,Ko HJ,Kim AS .2020 .Hyperhomocysteinaemia concurrent with metabolic syndrome is independently associated with chronic kidney disease among community-dwelling adults in an urban Korean population. Int J Environ Res Public Health, 10(18) : 6810.
Lamuno DG,Blanco FJA,Fuentes ED,Visa MTF,Conejo MM,Quintana LP .2023 .Hyperhomocysteinaemia in adult patients: A treatable metabolic condition. Nutrients, 10(1) : 135.
Liu PT,Chen JD .2021 .Synergistic association of hyperuricemia and Hyperhomocysteinaemia with chronic kidney disease in middle-aged adults and the elderly population. Medicine (Baltimore), 10(37) : 0000-000000027202.
Sen U,Mishra PK,Tyagi N,Tyagi SC .2010 .Homocysteine to hydrogen sul de or hypertension. Cell Biochem Biophys, 10(2-3) : 49-58.
Thampi P,Stewart BW,Joseph L,Melnyk SB,Hennings LJ,Nagarajan S. .2007 .Dietary homocysteine promotes atherosclerosis in apoe-de cient mice by inducing scavenger receptors expression. Atherosclerosis, 09(2) : 620-9.
Badri S,Vahdat S,Pourfarzam S,Shahraki M,Ataei TG,S TG .2021 .Homocysteine-lowering interventions in chronic kidney disease. J Res Pharm Pract, 75(3) : 21-24.
Cianciolo G,De Pascalis A,Di Lullo L,Ronco C,Zannini C .2017 .Folic acid and homocysteine in chronic kidney disease and cardiovascular disease progression: Which comes rst?. Cardiorenal Med, 10(4) : 255-66.
Long Y,Nie J .2016 .Homocysteine in renal injury. Kidney Dis, 10(2) : 80-7.
Chen CH,Yeh EL,Chen CC,Huang SC,Huang YC .2017 .Vitamin B-6, independent of homocysteine, is a signi cant factor in relation to in ammatory responses for chronic kidney disease and hemodialysis patients. Biomed Res Int, 10 : 1-8.
Postovitenko KP,Iliuk IA,Shevchuk SV,Bezsmertna GV,Bezsmertnyi O,Kurylenko IV .2017 .Hyperhomocysteinaemia in patients with chronic kidney disease and its relationship with the functional status of the cardiovascular system. Regul Mech Biosyst, 10(2) : 141-51.
Iqbal MP .2006 .Hyperhomocysteinaemia and coronary artery disease in Pakistan. J Pak Med Assoc, 56(6) : 282-5.
Yakub M,Iqbal MP,Iqbal R .2010 .Dietary patterns are associated with Hyperhomocysteinaemia in an urban Pakistani population. J Nutr, 10(7) : 1261-6.
Ansari T,Jami A,Rabbani B,Ghazanfar B,Khalil M,Jamal Q. .2020 .Frequency of elevated plasma homocysteine (Hcy) levels among type 2 Diabetes mellitus (T2DM) patients. Prof Med J, 10 : 635-40.
0

Citations

0

Downloads

107

Views